title: Mu opiate receptor gene dose effects on different morphine actions: evidence for differential in vivo mu receptor reserve.
abstract: Homozygous transgenic knockout mice without mu-opioid receptors lack morphine-induced antinociception, locomotion, tolerance, physical dependence, and reward. mu receptors thus appear to play central roles in these morphine actions. Different levels of mu receptor expression are found in different humans and in different animal strains. In vitro studies indicate that some morphine responses persist after inactivation of as many as 90% of the initial mu receptor complement, while others are attenuated after inactivating many fewer receptors. Varying levels of mu receptor reserve could thus exist in different mu-expressing neuronal populations in vivo. Heterozygous mu receptor knockout mice express half of wild-type mu receptor levels. Tests of morphine actions in these mice reveal evidence for differing mu receptor reserves in brain circuits that mediate distinct opiate effects. Heterozygotes display attenuated locomotion, reduced morphine self-administration, intact tolerance, rightward shifts in morphine lethality dose/effect relationships, and variable effects on place preference compared to wild-type mice. They demonstrate full physical dependence, as measured by naloxone-precipitated abstinence following five days of morphine administration. Neuroadaptive changes in sites other than mu receptors could be involved in some of these results. Nevertheless, these data document substantial influences that individual differences in levels of mu receptor expression could exert on distinct opiate drug effects. They support the idea that functional mu receptor reserve differs among the diverse neuronal populations that mediate distinct properties of opiate drugs.
authors.affiliation: Molecular Neurobiology Branch, NIDA-IRP, NIH, Baltimore, MD, USA
authors.forename: I
authors.initials: I
authors.lastname: Sora
authors.forename: G
authors.initials: G
authors.lastname: Elmer
authors.forename: M
authors.initials: M
authors.lastname: Funada
authors.forename: J
authors.initials: J
authors.lastname: Pieper
authors.forename: X F
authors.initials: XF
authors.lastname: Li
authors.forename: F S
authors.initials: FS
authors.lastname: Hall
authors.forename: G R
authors.initials: GR
authors.lastname: Uhl
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D001923:Brain Chemistry / Q000187:drug effects / Q000235:genetics*; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D005260:Female; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics / Q000378:metabolism*; D009020:Morphine / Q000494:pharmacology*; D009021:Morphine Dependence / Q000503:physiopathology; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism; D010147:Pain Measurement / Q000187:drug effects; D017450:Receptors, Opioid, mu / Q000172:deficiency* / Q000187:drug effects / Q000235:genetics*; D012201:Reward; D012646:Self Administration
chemical_list: D009292:Narcotic Antagonists; D009294:Narcotics; D017450:Receptors, Opioid, mu; D009270:Naloxone; D009020:Morphine